What it does
Invests in companies developing new drugs. The team believe that an ageing global population means there is a growing need for these.

What it invests in
It looks for companies with an experienced management team targeting an unmet need. About 41% of its assets are in companies focused on cancer, such as the German firm MorphoSys. Four-fifths of its assets are American.

The lead fund manager, Carl Harald Janson, said: “We are good at innovation in the UK and Europe but a lot of those inventions tend to get bought and end up in America.”

The Times – Fund Focus

 

 

Disclaimer

  • You are seeing this because you are accessing IBT’s website for the first time.
  • The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.
  • An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.
  • The material on this website is intended to be viewed only by persons resident in the EEA.
  • The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.
  • No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.
  • The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).